Can Lithium Cause Suicidal Thoughts?

Lithium does not cause suicidal thoughts. In fact, it is one of the most consistently anti-suicidal medications in psychiatry, with decades of evidence showing it lowers the risk of suicide in people with mood disorders. The concern is understandable, especially given the well-known FDA black-box warnings on antidepressants, but lithium occupies a different pharmacological category and has a strikingly different track record. The real danger with lithium and suicidality lies not in taking it but in stopping it abruptly.

What the Evidence Actually Shows

A large systematic review and meta-analysis pooling 48 randomized controlled trials found that lithium reduced the number of completed suicides compared with placebo by a wide margin, and also reduced deaths from any cause.¹ That protective effect held in people with unipolar depression as well as bipolar disorder, which is worth knowing because lithium is often associated exclusively with bipolar treatment in the public mind.

What makes lithium unusual among psychiatric medications is that its anti-suicidal effect appears to operate partly independently of mood stabilization. Even when someone’s mood symptoms are not fully controlled, and even when blood levels of lithium sit below the range typically considered “therapeutic,” the drug still seems to reduce suicidal behavior.² That hints at a mechanism beyond simply preventing depressive or manic episodes.

A more recent systematic review focused specifically on whether lithium might increase non-fatal suicidal behavior found no difference in rates of suicide attempts or other self-harm between lithium and comparison groups in the trials that reported those outcomes.³ In other words, even when you look at sub-lethal suicidal acts rather than completed suicides, there is no signal that lithium pushes people toward self-harm.

Why People Ask This Question in the First Place

If you have been prescribed lithium or are considering it, the worry about suicidal thoughts is entirely reasonable. Several things feed the concern. First, there is the FDA’s well-publicized black-box warning on antidepressants, which states that some antidepressants can increase suicidal thinking in children and young adults. People often assume that all psychiatric medications carry a similar risk. Lithium is not an antidepressant, though, and it does not share the same pharmacological properties that prompted that warning.

Second, lithium is most commonly prescribed for bipolar disorder, a condition that carries one of the highest suicide rates of any psychiatric diagnosis. When someone taking lithium experiences suicidal thoughts, the source of those thoughts is overwhelmingly the illness itself, not the medication. Disentangling medication effects from disease effects is genuinely hard in clinical practice, and clinicians take any new suicidal thinking seriously regardless of cause. But the weight of evidence points clearly toward lithium being protective rather than harmful.

Third, lithium can cause subjective side effects that feel alarming. Some people experience emotional blunting, a sense that their emotional range has been compressed or dulled. About 5 to 6 percent of people on lithium report this, and it is one of the more common reasons patients choose to stop the medication on their own.⁴ Emotional blunting is distressing, and for some people it can feel like a loss of self. But it is a different experience from suicidal ideation, and the research does not show that it leads to suicidal thoughts on its own.

How Lithium Likely Works Against Suicidality

Researchers believe lithium has specific biological properties that reduce impulsive and aggressive behavior, which are two of the strongest proximal risk factors for suicide attempts. At the cellular level, lithium promotes increased inhibition of neuronal activity and dampens the excitatory drive from overactive stress-response systems, including excessive release of the stress-related chemical norepinephrine.⁵ In plainer terms, lithium appears to turn down the volume on the brain’s “act now” signals during moments of extreme distress.

The BMJ meta-analysis noted this as well, concluding that while lithium likely prevents suicide partly by preventing mood episode relapses, additional mechanisms including reductions in aggression and impulsivity are probably also at play.¹ This dual action matters because it means lithium is not merely treating the mood disorder and hoping the suicide risk follows along. It seems to directly address the behavioral pathways that turn suicidal thoughts into suicidal acts.

The Real Danger With Lithium and Suicide

If there is a genuine crisis point in lithium treatment, it is not starting the medication. It is stopping it. Published data indicate that in the first year after lithium discontinuation, affective illness recurred in roughly two-thirds of patients, and rates of suicidal acts rose dramatically, with fatalities about fourteen times more frequent after stopping lithium than during treatment.⁶ The spike in risk was concentrated early after discontinuation and was substantially worse when lithium was stopped abruptly rather than tapered slowly.

This is a critical practical point. People stop lithium for all sorts of reasons: side effects, feeling well enough to think they no longer need it, difficulty with the regular blood tests that lithium requires, or simply forgetting. But the rebound in suicidal risk after abrupt discontinuation is one of the most dangerous moments in the management of bipolar disorder. If you are on lithium and considering stopping, a gradual taper under medical supervision meaningfully reduces the rebound risk compared to stopping suddenly.⁶

A recent study that followed patients before and during lithium treatment found a nearly fivefold decrease in suicidal events once lithium was added to treatment, dropping from about 48 percent of observations with suicidal events before lithium to roughly 10 percent during lithium use.⁷ The time between suicidal episodes also stretched out during lithium treatment. These are within-person comparisons, which are more convincing than comparing different groups of patients who might differ in severity.

How Lithium Compares to Other Mood Stabilizers

Lithium is not the only mood stabilizer in use. Valproate (sold under brand names like Depakote) is widely prescribed as well, and the two are frequently compared. In a large prospective study following roughly 50,000 people with bipolar disorder over eight years, lithium reduced the rate of suicide-related events by about 14 percent during treatment periods compared to the same individuals’ periods off medication. Valproate showed no such reduction. The difference between the two drugs was statistically significant, and the researchers estimated that about 12 percent of all suicide-related events in the study population could have been prevented if patients had been on lithium continuously throughout the follow-up.⁸

Evidence-based guidelines reflect this difference. Reviews of the literature suggest lithium is a better treatment choice specifically for patients at high risk for suicide, among other clinical factors like a positive family history of bipolar disorder and fewer previous hospitalizations.⁹ Valproate has its own clinical advantages for certain patient profiles, but when suicide prevention is a priority, lithium has a stronger evidence base.

Does Age Matter?

The question of whether lithium’s protective effect varies by age has produced somewhat mixed results. One study found that age significantly moderated lithium’s anti-suicidal effect compared to valproate: people over about 42 years old on lithium had a substantially lower risk of suicidal behavior than younger patients on either medication or older patients on valproate.¹⁰ This could suggest the drug works better in older adults, possibly because their illness patterns respond more consistently to lithium or because they are more adherent to treatment.

However, a different study using a registry-based design found no significant interaction between age and lithium’s effect on suicide rates.¹¹ The discrepancy likely reflects differences in study design and what drug lithium was being compared to. The safest interpretation is that lithium appears to be protective across age groups, with the possibility that older adults derive an extra benefit that younger adults do not, though the evidence is not settled enough to declare a firm cutoff.

For young people specifically, neither the FDA nor the research literature has flagged lithium as carrying the same kind of age-related suicidality risk that prompted the antidepressant black-box warning. Lithium acts through different brain pathways, and its track record in adolescents and young adults, while less studied than in middle-aged populations, does not show the emergent suicidal ideation pattern seen with some antidepressants.

Why People Stop Lithium and Why That Matters

Understanding why people stop lithium is essential because, as discussed earlier, discontinuation is the single biggest suicide-related risk associated with the drug. The reasons are varied and not always dramatic. The retrospective cohort study mentioned above found that emotional blunting was the psychological side effect most likely to prompt patients to stop lithium on their own, without medical guidance. Patients stopped for this reason more often than doctors recommended stopping.⁴

Other common reasons include weight gain, thyroid problems, kidney concerns, tremor, and the inconvenience of regular blood monitoring. Lithium has a narrow therapeutic window, meaning the difference between an effective dose and a toxic one is relatively small, so regular lab work is necessary. Some people find this burden manageable; others find it drives them away from treatment. Real-world data support the idea that integrating accessible testing, early management of side effects, clear education about toxicity, and suicide-specific safety planning into lithium care can help people stay on treatment.¹²

If you are experiencing side effects from lithium and considering stopping, talk to your prescriber first. Dose adjustments, slower titration, or switching to an extended-release formulation can address many side effects without requiring complete discontinuation. And if you do need to stop, a gradual taper can cut the rebound risk considerably.

Lithium in Drinking Water and Population Suicide Rates

One of the more surprising corners of lithium research involves trace amounts of the element that occur naturally in some municipal water supplies. The concentrations are far below what anyone would take as medication, yet a meta-analysis of ecological studies found a consistent inverse relationship between lithium levels in drinking water and suicide rates at the population level.¹³ Areas with higher natural lithium in their water tended to have lower suicide mortality, and the association held for both men and women, though it was more statistically robust for women.

Further research has added nuance. One study found the inverse association between water lithium and suicide was significant only in municipalities with relatively higher lithium levels and with a high rate of affective disorders, suggesting a threshold effect rather than a smooth linear relationship.¹⁴ Another analysis in Austria confirmed the negative association between natural water lithium and suicide, though the effect was intertwined with lithium prescribing patterns in those areas, making it hard to isolate the water contribution.¹⁵

These ecological findings are intriguing but should be interpreted cautiously. They cannot prove causation because many other factors differ between high-lithium and low-lithium regions. Nobody is recommending adding lithium to water supplies. But the consistency of the signal across multiple countries and studies reinforces the broader point that lithium, even in tiny amounts, trends in the opposite direction from what you would expect if it caused suicidal thinking.

Genetics and the Future of Personalized Lithium Treatment

Not everyone responds to lithium equally, and researchers have been trying to figure out why. The search for genetic markers that predict lithium response, including its anti-suicidal effects, is still in early stages. A review of the literature found mixed results overall, though one genetic variation in the gene encoding the serotonin transporter showed a potential correlation with both vulnerability to suicide and a poor response to lithium.¹⁶ If validated, this kind of finding could eventually help clinicians identify patients who are less likely to benefit from lithium and steer them toward alternatives earlier.

For now, predicting who will respond well to lithium remains more art than science. Clinical features like a classic bipolar presentation with distinct manic and depressive episodes, a family history of bipolar disorder, and fewer prior hospitalizations tend to predict a better response. Patients with heavy substance use comorbidities, rapid cycling, or mixed episodes tend to have a harder time on lithium. None of these clinical predictors specifically relate to suicidal thinking. They are about overall treatment response, with suicide risk reduction as one downstream benefit of good response.

The genetic research matters less for what it says today and more for where it points. Psychiatry has historically relied on trial and error with medications, and lithium is no exception. If genomic testing eventually narrows down who will get the most anti-suicidal benefit from lithium versus other agents, that represents a meaningful advance in a field where treatment decisions still depend heavily on clinical intuition and patient tolerance of side effects.